Loading clinical trials...
Loading clinical trials...
A Phase 3b Clinical Study to Assess Whether Regular Administration of ADVATE in the Absence of Immunological Danger Signals Reduces the Incidence Rate of Inhibitors in Previously Untreated Patients With Hemophilia A
Conditions
Interventions
Recombinant antihemophilic factor, plasma/albumin-free method (rAHF-PFM)
Locations
19
United States
Indianapolis, Indiana, United States
New Brunswick, New Jersey, United States
Vienna, Austria
Sofia, Bulgaria
Kingston, Ontario, Canada
Brno, Czechia
Start Date
August 26, 2011
Primary Completion Date
November 16, 2012
Completion Date
November 16, 2012
Last Updated
May 24, 2021
NCT07226206
NCT05987449
NCT04645199
NCT06703606
NCT06702579
NCT03818763
Lead Sponsor
Baxalta now part of Shire
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions